Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Bupropion works differently from most antidepressants. Instead of affecting serotonin, it blocks the reabsorption of noradrenaline and dopamine — two brain chemicals involved in mood, motivation, and attention. When your family member takes bupropion, much of its effect actually comes from compounds the body creates when it breaks the medication down. These breakdown products, particularly one called hydroxybupropion, build up in the bloodstream and stay active for longer than the original medication. The elimination half-life of bupropion itself is around 20 hours, but the active breakdown products last 33 to 37 hours, which means they accumulate with repeated doses.
In Australia, bupropion is approved only for helping people quit smoking, used alongside counselling. It's not approved here for depression, though it is used that way in some other countries. If your family member is taking it for a reason other than smoking cessation, that's what's called off-label use — legal and sometimes appropriate, but worth understanding.
Side effects you might notice include trouble sleeping, dry mouth, nausea, headache, or dizziness. Seizures are a serious risk, and bupropion cannot be used in anyone who has ever had a seizure, has a brain tumour, or is withdrawing from alcohol or benzodiazepines. It's also contraindicated in people with current or past eating disorders like bulimia or anorexia nervosa. Very rarely, severe allergic reactions or serious skin reactions can occur.
Bupropion is broken down in the liver by an enzyme called CYP2B6, and it also blocks another enzyme, CYP2D6. This means it can interact with other medications that use those same pathways, so any prescriber needs a full list of what your family member is taking.
Nicotine dependence Clinical criteria: Treatment Phase: Commencement of a short-term (9 weeks) course of treatment The treatment must be as an aid to achieving abstinence from smoking, AND The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must have indicated they are ready to cease smoking, AND Patient must not receive more than 9 weeks of PBS-subsidised treatment with this drug per 12-month period. Treatment criteria: Patient must be undergoing concurrent counselling for smoking cessation through a comprehensive support and counselling program or is about to enter such a program at the time PBS-subsidised treatment is initiated. Details of the support and counselling program must be documented in the patient's medical records at the time treatment is initiated.
“Bupropion is a selective inhibitor of the neuronal re-uptake of catecholamines (noradrenaline and dopamine) with minimal effect on the re-uptake of indolamines (serotonin) and no inhibitory effect on monoamine oxidase.”
“The mean elimination half-life of bupropion is approximately 20 hours. The elimination half-life of hydroxybupropion is approximately 20 hours and its area under the plasma drug concentration versus time curve (AUC) at steady state is approximately 14 to 17 times that of bupropion. The elimination half-lives for threohydrobupropion and erythrohydrobupropion are longer (37 and 33 hours, respectively) and steady-state AUC values are 8 and 1.6 times higher than that of bupropion, respectively.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Bupropion is a norepinephrine–dopamine reuptake inhibitor (NDRI) and negative allosteric modulator of several nicotinic acetylcholine receptors. Its pharmacological activity is substantially mediated by active metabolites—hydroxybupropion, threohydrobupropion, and erythrohydrobupropion—present in plasma at levels comparable to or exceeding the parent compound. Bupropion has no meaningful direct activity at adrenergic, dopaminergic, serotonergic, histaminergic, or muscarinic receptors and does not inhibit monoamine oxidase. TGA-approved indications are limited to short-term adjunctive therapy for nicotine dependence in adults committed to quitting, when used alongside counselling for smoking cessation.
Bupropion is metabolised primarily via CYP2B6 to hydroxybupropion; care is required when co-prescribing with CYP2B6 inducers or inhibitors. Although bupropion is not a CYP2D6 substrate, both the parent compound and hydroxybupropion inhibit the CYP2D6 pathway, raising the potential for interactions with drugs metabolised by that enzyme. The parent compound has an elimination half-life of approximately 20 hours; the active metabolites have longer half-lives (hydroxybupropion 20 hours, threohydrobupropion 37 hours, erythrohydrobupropion 33 hours), with steady-state AUC values substantially higher than that of bupropion.
Contraindications include current or prior seizure disorder, CNS tumour, current or previous bulimia or anorexia nervosa, abrupt alcohol or benzodiazepine withdrawal, and concomitant MAOI use (14-day washout required). Seizure risk is dose-dependent; concurrent use of multiple bupropion-containing preparations is contraindicated. Common adverse effects include insomnia, dry mouth, nausea, headache, and dizziness. Serious adverse effects include seizures, anaphylaxis, Stevens–Johnson syndrome, toxic epidermal necrolysis, and angle-closure glaucoma.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro findings indicate that bupropion is metabolised to its major active metabolite hydroxybupropion primarily by the cytochrome P450 IIB6 (CYP2B6) (see Section 5.2 PHARMACOKINETIC PROPERTIES ). Care should therefore be exercised when ZYBAN SR is co-administered with drugs known to affect the CYP2B6 isoenzyme (e.g. orphenadrine, cyclophosphamide, ifosfamide, ticlopidine, clopidogrel). Although bupropion is not metabolised by the CYP2D6 isoenzyme, in vitro human P450 studies have shown that bupropion and hydroxybupropion are inhibitors of the CYP2D6 pathway.”